Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CDOP regimen for newly diagnosed diffuse large B-cell lymphoma
ChiCTR2100044994Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100044994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044994.